Search research articles
Contact Us
Filters
Showing results (31-40 of 130) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2000
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia
N Vey, F J Giles, H Kantarjian, et al.
Lancet (London, England)
|
March 7, 1987
Perforation of superior vena cava by indwelling central venous catheters
S J Russell, F J Giles, D Edwards, et al.
Hematology (Amsterdam, Netherlands)
|
July 15, 2016
A BCNU-containing Regimen, Mini-BEAM, with GM-CSF is a Safe and Effective Mobilizing Regimen Pre-stem Cell Transplantation in Lymphoma Patients
F J Giles, A Jacobs, S H Pepkowitz, et al.
Cancer Immunology, Immunotherapy : CII
|
January 1, 1991
Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias
S H Lim, C Worman, A Jewell, et al.
Leukemia & Lymphoma
|
May 9, 2001
Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia
J R Beck, J Guilhot, F J Giles, et al.
Leukemia
|
September 30, 2005
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells
R-H Xu, H Pelicano, H Zhang, et al.
Leukemia
|
December 1, 2006
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma
T Haritunians, A Mori, J O'Kelly, et al.
The British Journal of Dermatology
|
June 25, 2017
Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database
A G Florek, B Nardone, S Thareja, et al.
Leukemia & Lymphoma
|
August 1, 1992
Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells
A P Jewell, C P Worman, F J Giles, et al.
Biotechniques
|
May 18, 2001
Highly reproducible detection and semi-quantification of telomerase activity
S Verstovsek, T Manshouri, H Kantarjian, et al.
Page
of 13
Search research articles
Search
Showing results (31-40 of 130) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2000
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia
N Vey, F J Giles, H Kantarjian, et al.
Lancet (London, England)
|
March 7, 1987
Perforation of superior vena cava by indwelling central venous catheters
S J Russell, F J Giles, D Edwards, et al.
Hematology (Amsterdam, Netherlands)
|
July 15, 2016
A BCNU-containing Regimen, Mini-BEAM, with GM-CSF is a Safe and Effective Mobilizing Regimen Pre-stem Cell Transplantation in Lymphoma Patients
F J Giles, A Jacobs, S H Pepkowitz, et al.
Cancer Immunology, Immunotherapy : CII
|
January 1, 1991
Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias
S H Lim, C Worman, A Jewell, et al.
Leukemia & Lymphoma
|
May 9, 2001
Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia
J R Beck, J Guilhot, F J Giles, et al.
Leukemia
|
September 30, 2005
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells
R-H Xu, H Pelicano, H Zhang, et al.
Leukemia
|
December 1, 2006
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma
T Haritunians, A Mori, J O'Kelly, et al.
The British Journal of Dermatology
|
June 25, 2017
Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database
A G Florek, B Nardone, S Thareja, et al.
Leukemia & Lymphoma
|
August 1, 1992
Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells
A P Jewell, C P Worman, F J Giles, et al.
Biotechniques
|
May 18, 2001
Highly reproducible detection and semi-quantification of telomerase activity
S Verstovsek, T Manshouri, H Kantarjian, et al.
Page
of 13